SE443923B - Lekemedelsberedning for behandling av bakteriella angrepp innehallande erytromycin och metoklopramin - Google Patents

Lekemedelsberedning for behandling av bakteriella angrepp innehallande erytromycin och metoklopramin

Info

Publication number: SE443923B
Authority: SE; Sweden
Prior art keywords: erythromycin; metoclopramide; base; preparation according; weight
Prior art date: 1977-06-03

Application number

SE7806441A

Other languages

English (en)

Swedish (sv)

Other versions

SE7806441L (sv

Inventor

P Barbier

Original Assignee

Ile De France

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-06-03

Filing date

1978-06-01

Publication date

1986-03-17

1978-06-01 Application filed by Ile De France filed Critical Ile De France

1978-12-04 Publication of SE7806441L publication Critical patent/SE7806441L/xx

1986-03-17 Publication of SE443923B publication Critical patent/SE443923B/sv

Links

ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims description 82
238000011282 treatment Methods 0.000 title claims description 5
230000001580 bacterial effect Effects 0.000 title claims 2
239000000825 pharmaceutical preparation Substances 0.000 title claims 2
229960003276 erythromycin Drugs 0.000 claims description 38
210000002966 serum Anatomy 0.000 claims description 23
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 20
229960004503 metoclopramide Drugs 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 3
238000009472 formulation Methods 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 claims 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims 1
206010061217 Infestation Diseases 0.000 claims 1
231100000614 poison Toxicity 0.000 claims 1
239000003440 toxic substance Substances 0.000 claims 1
229920002472 Starch Polymers 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000008107 starch Substances 0.000 description 6
235000019698 starch Nutrition 0.000 description 6
239000001913 cellulose Substances 0.000 description 5
229920002678 cellulose Polymers 0.000 description 5
235000010980 cellulose Nutrition 0.000 description 5
206010037660 Pyrexia Diseases 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
-1 erythromycin ester Chemical class 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
238000000034 method Methods 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000003322 Coinfection Diseases 0.000 description 2
239000000969 carrier Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000037406 food intake Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
HPPDSFRJRMUHSC-UHFFFAOYSA-N 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxybenzamide;hydron;dichloride Chemical compound Cl.Cl.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC HPPDSFRJRMUHSC-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000606124 Bacteroides fragilis Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
241000589562 Brucella Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000019505 Deglutition disease Diseases 0.000 description 1
241000186811 Erysipelothrix Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
241000186779 Listeria monocytogenes Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000606856 Pasteurella multocida Species 0.000 description 1
206010067268 Post procedural infection Diseases 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
208000003217 Tetany Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
238000010009 beating Methods 0.000 description 1
230000036765 blood level Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
229950000206 estolate Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000001788 irregular Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960002787 metoclopramide dihydrochloride Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000002547 new drug Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940051027 pasteurella multocida Drugs 0.000 description 1
150000003151 propanoic acid esters Chemical class 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

SE7806441A 1977-06-03 1978-06-01 Lekemedelsberedning for behandling av bakteriella angrepp innehallande erytromycin och metoklopramin SE443923B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB23727/77A GB1577196A (en)	1977-06-03	1977-06-03	Compositions containing erythromycin and metoclopramide

Publications (2)

Publication Number	Publication Date
SE7806441L SE7806441L (sv)	1978-12-04
SE443923B true SE443923B (sv)	1986-03-17

Family

ID=10200309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7806441A SE443923B (sv)	1977-06-03	1978-06-01	Lekemedelsberedning for behandling av bakteriella angrepp innehallande erytromycin och metoklopramin

Country Status (15)

Country	Link
US (1)	US4176180A (fr)
JP (1)	JPS545047A (fr)
AU (1)	AU519743B2 (fr)
BE (1)	BE867396A (fr)
CA (1)	CA1119097A (fr)
CH (1)	CH631623A5 (fr)
DE (1)	DE2823655C3 (fr)
GB (1)	GB1577196A (fr)
HK (1)	HK40582A (fr)
IE (1)	IE46984B1 (fr)
IT (1)	IT1156786B (fr)
NL (1)	NL177180C (fr)
NZ (1)	NZ187401A (fr)
SE (1)	SE443923B (fr)
ZA (1)	ZA783131B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59107354U (ja) *	1983-01-08	1984-07-19	三菱電機株式会社	フライホイ−ル装置
US5081153A (en) *	1984-05-17	1992-01-14	Beecham Group P.L.C.	Sterile parenteral composition
HUP9701293A3 (en) *	1997-07-25	1999-08-30	Chinoin Gyogyszer Es Vegyeszet	New salts without unsavoury taste and pharmaceutical compositions containing them
US6428805B1 (en) *	1998-08-26	2002-08-06	Teijin Limited	Powdery nasal compositions
IN192748B (fr) *	2000-08-29	2004-05-15	Ranbaxy Lab Ltd
US6878751B1 (en) *	2000-10-19	2005-04-12	Imperial College Of Science Technology And Medicine	Administration of resveratrol to treat inflammatory respiratory disorders
WO2003017981A1 (fr)	2001-08-29	2003-03-06	Ranbaxy Laboratories Limited	Formulation a liberation controlee de clarithromycine ou de tinidazol
EA200400343A1 (ru) *	2001-08-29	2004-08-26	Рэнбакси Лабораториз Лимитед	Композиция с контролируемым высвобождением кларитромицина или тинидазола
WO2008068584A2 (fr) *	2006-12-05	2008-06-12	University Of Witwatersrand, Johannesburg	Système de libération de médicament gastro-intestinal multiparticulaire à configuration hétérogène

1977
- 1977-06-03 GB GB23727/77A patent/GB1577196A/en not_active Expired
1978
- 1978-05-24 BE BE1008893A patent/BE867396A/fr not_active IP Right Cessation
- 1978-05-29 CA CA000304347A patent/CA1119097A/fr not_active Expired
- 1978-05-29 NZ NZ187401A patent/NZ187401A/xx unknown
- 1978-05-30 DE DE2823655A patent/DE2823655C3/de not_active Expired
- 1978-05-30 IT IT49615/78A patent/IT1156786B/it active
- 1978-05-31 NL NLAANVRAGE7805897,A patent/NL177180C/xx not_active IP Right Cessation
- 1978-06-01 SE SE7806441A patent/SE443923B/sv not_active IP Right Cessation
- 1978-06-01 US US05/911,611 patent/US4176180A/en not_active Expired - Lifetime
- 1978-06-01 CH CH602578A patent/CH631623A5/fr not_active IP Right Cessation
- 1978-06-01 ZA ZA00783131A patent/ZA783131B/xx unknown
- 1978-06-02 IE IE1117/78A patent/IE46984B1/en not_active IP Right Cessation
- 1978-06-02 AU AU36837/78A patent/AU519743B2/en not_active Expired
- 1978-06-02 JP JP6716778A patent/JPS545047A/ja active Granted
1982
- 1982-09-16 HK HK405/82A patent/HK40582A/xx unknown

Also Published As

Publication number	Publication date
AU519743B2 (en)	1981-12-17
IT7849615A0 (it)	1978-05-30
GB1577196A (en)	1980-10-22
NL7805897A (nl)	1978-12-05
JPS5620285B2 (fr)	1981-05-13
JPS545047A (en)	1979-01-16
NZ187401A (en)	1981-05-29
US4176180A (en)	1979-11-27
IE781117L (en)	1978-12-03
IT1156786B (it)	1987-02-04
SE7806441L (sv)	1978-12-04
DE2823655B2 (de)	1980-07-10
BE867396A (fr)	1978-11-24
ZA783131B (en)	1979-06-27
NL177180C (nl)	1985-08-16
AU3683778A (en)	1979-12-06
IE46984B1 (en)	1983-11-16
NL177180B (nl)	1985-03-18
CH631623A5 (fr)	1982-08-31
CA1119097A (fr)	1982-03-02
DE2823655A1 (de)	1978-12-07
HK40582A (en)	1982-09-24
DE2823655C3 (de)	1981-07-16

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 7806441-7

Effective date: 19930109

Format of ref document f/p: F

Publication	Publication Date	Title
KR910004573B1 (ko)	1991-07-06	작용 지속형 세파클로르 제제의 제조 방법
KR100404293B1 (ko)	2004-02-18	경구투여용조성물
SE461854B (sv)	1990-04-02	Acetylerytromycinstearat och terapeutisk komposition innehaallande det
EP0222914A1 (fr)	1987-05-27	Preparation antibiotique granulaire composite stabilisee
SE443923B (sv)	1986-03-17	Lekemedelsberedning for behandling av bakteriella angrepp innehallande erytromycin och metoklopramin
AU3774889A (en)	1990-01-12	Pharmaceutical dosage form for the medication of fish
CN102784159A (zh)	2012-11-21	兽用注射用复方增效酒石酸泰乐菌素
CN117379378A (zh)	2024-01-12	一种兽用复方阿莫西林可溶性粉及其制备工艺
CN113350297B (zh)	2022-11-04	一种替米考星干混悬剂及其制备方法
CN107875154B (zh)	2021-05-14	含有哌拉西林的组合物、其药物制剂及其应用
CN117547513A (zh)	2024-02-13	一种兽用复方阿莫西林可溶性粉及其制备方法
CN103301075A (zh)	2013-09-18	一种头孢克肟组合物混悬颗粒剂及其制备方法
CN113116859B (zh)	2022-08-30	阿奇霉素丸芯包衣制剂
EP0413299A1 (fr)	1991-02-20	Composition antibiotique
JPS6337770B2 (fr)	1988-07-27
CN118924716B (zh)	2025-01-28	萘替芬在抗脓肿分枝杆菌感染中的应用
CN107320482A (zh)	2017-11-07	一种适用于儿童服用的阿奇霉素药物组合物
CN101653428A (zh)	2010-02-24	利福昔明肠溶制剂组合物及其制备方法
CN1091660A (zh)	1994-09-07	银黄冲剂及其制备方法和检验方法
CN110812363A (zh)	2020-02-21	含有三取代膦氧化物与氧杂环丁酮衍生物的组合物及其用途
CN118924715B (zh)	2025-03-21	布替萘芬在抗脓肿分枝杆菌感染中的应用
US3013942A (en)	1961-12-19	Therapeutic erythromycin ester compositions
CN103405466B (zh)	2015-01-21	复方增效酒石酸泰乐菌素
RU2498803C1 (ru)	2013-11-20	Противотуберкулезное лекарственное средство
JP2993812B2 (ja)	1999-12-27	ホスホマイシンを有効成分とする魚類のパスツレラ属細菌性類結節症治療剤